Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors
Highlight
This study investigates retreatment rates and timing in infants treated with primary laser photocoagulation versus intravitreal bevacizumab injection for retinopathy of prematurity (ROP). Key findings include a significantly lower early retreatment rate in the bevacizumab group compared to laser-treated eyes, with retreatment mainly confined to micro- or nano-premature infants (<27 weeks gestational age or <800 grams). Aggressive ROP (AROP) predicted earlier retreatment, and bevacizumab delayed the need for additional interventions.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.